Pretreatment characteristics of 13 patients with CAD and effect of eculizumab on frequency of RBC transfusion and levels of lactate dehydrogenase and hemoglobin
| Patient identification number . | Pretreatment characteristics . | Treatment results . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, y/sex . | Disease duration, mo . | No. of prior therapies . | No. of RBC units expected* . | No. of RBC units received† . | Lactate dehydrogenase, U/L . | Hemoglobin, g/dL . | |||||
| Week 0 . | Week 26 . | Week 34 . | Week 0 . | Week 26 . | Week 34 . | ||||||
| Lactate dehydrogenase decrease <250 U/L, chronic CAD | |||||||||||
| 1‡ | 77/female | 42 | 0 | 1.3 | 0 | 545 | 378 | 268 | 10.8 | 11.5 | 9.9 |
| 3 | 72/male | 16 | 0 | 1.3 | 0 | 572 | 567 | 471 | 9.0 | 10.4 | 9.8 |
| 6 | 75/female | 87 | 2 | 0 | 0 | 797 | (800)§ | (899)§ | 11.6 | (11.5)§ | (13.0)§ |
| 11 | 78/female | 61 | 2 | 20.9 | 4 | 450 | 334 | 539 | (8.5)║ | 9.1 | 9.1 |
| 12 | 74/female | 7 | 0 | 2.6 | 0 | 514 | 327 | 809 | 8.3 | 8.5 | 8.6 |
| 13 | 64/female | 193 | 0 | 3.9 | 0 | 638 | 1127 | 919 | 10.8 | 10.1 | (11.1)¶ |
| Lactate dehydrogenase decrease ≥250 U/L, chronic CAD | |||||||||||
| 4‡ | 73/female | 5 | 3 | 3.9 | 0 | 625 | 243 | 231 | 8.8 | 8.9 | 9.6 |
| 7 | 80/female | 221 | 5 | 5.2 | 0 | 685 | 353 | 305 | 8.3 | 9.4 | 9.6 |
| 9 | 74/male | 42 | 3 | 2.1 | 0 | 534 | (211)# | n.d.# | 9.5 | (8.1)# | n.d.# |
| 10 | 69/female | 15 | 0 | 0 | 0 | 566 | (282)** | 683 | 9.5 | 12.1 | 11.8 |
| 14 | 73/male | 80 | 4 | 0 | 12 | 719 | 243 | 414 | (8.8)†† | 8.8 | 10.5 |
| 15 | 76/female | 10 | 0 | 0 | 0 | 453 | 194 | 486 | 9.2 | 11.2 | 9.5 |
| Lactate dehydrogenase decrease ≥250 U/L, acute CAS | |||||||||||
| 5 | 73/female | 1 | 1 | 5.2 | 0 | 2980 | 144 | 154 | 9.6 | 10.2 | 11.4 |
| Patient identification number . | Pretreatment characteristics . | Treatment results . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, y/sex . | Disease duration, mo . | No. of prior therapies . | No. of RBC units expected* . | No. of RBC units received† . | Lactate dehydrogenase, U/L . | Hemoglobin, g/dL . | |||||
| Week 0 . | Week 26 . | Week 34 . | Week 0 . | Week 26 . | Week 34 . | ||||||
| Lactate dehydrogenase decrease <250 U/L, chronic CAD | |||||||||||
| 1‡ | 77/female | 42 | 0 | 1.3 | 0 | 545 | 378 | 268 | 10.8 | 11.5 | 9.9 |
| 3 | 72/male | 16 | 0 | 1.3 | 0 | 572 | 567 | 471 | 9.0 | 10.4 | 9.8 |
| 6 | 75/female | 87 | 2 | 0 | 0 | 797 | (800)§ | (899)§ | 11.6 | (11.5)§ | (13.0)§ |
| 11 | 78/female | 61 | 2 | 20.9 | 4 | 450 | 334 | 539 | (8.5)║ | 9.1 | 9.1 |
| 12 | 74/female | 7 | 0 | 2.6 | 0 | 514 | 327 | 809 | 8.3 | 8.5 | 8.6 |
| 13 | 64/female | 193 | 0 | 3.9 | 0 | 638 | 1127 | 919 | 10.8 | 10.1 | (11.1)¶ |
| Lactate dehydrogenase decrease ≥250 U/L, chronic CAD | |||||||||||
| 4‡ | 73/female | 5 | 3 | 3.9 | 0 | 625 | 243 | 231 | 8.8 | 8.9 | 9.6 |
| 7 | 80/female | 221 | 5 | 5.2 | 0 | 685 | 353 | 305 | 8.3 | 9.4 | 9.6 |
| 9 | 74/male | 42 | 3 | 2.1 | 0 | 534 | (211)# | n.d.# | 9.5 | (8.1)# | n.d.# |
| 10 | 69/female | 15 | 0 | 0 | 0 | 566 | (282)** | 683 | 9.5 | 12.1 | 11.8 |
| 14 | 73/male | 80 | 4 | 0 | 12 | 719 | 243 | 414 | (8.8)†† | 8.8 | 10.5 |
| 15 | 76/female | 10 | 0 | 0 | 0 | 453 | 194 | 486 | 9.2 | 11.2 | 9.5 |
| Lactate dehydrogenase decrease ≥250 U/L, acute CAS | |||||||||||
| 5 | 73/female | 1 | 1 | 5.2 | 0 | 2980 | 144 | 154 | 9.6 | 10.2 | 11.4 |
Imputed values are given in parentheses.
n.d., not done; no., number.
Number of RBC units expected to be transfused within the 34-week study period, based on the transfusion requirement in the preceding 12 months.
Number of RBC units received within the 34-week study period.
After the end of the treatment phase, eculizumab was continued for another 38 weeks (patient 1) or 24 weeks (patient 4), respectively.
Imputed from week 18 (premature trial termination after 12 eculizumab infusions because of persistent Raynaud syndrome); week 34 values were obtained 8 weeks after the last eculizumab dose (ie, in week 26).
Imputed from week −2 (no reliable hemoglobin value available in week 0).
Imputed from week 30 (no reliable hemoglobin value available in week 34).
Imputed from week 4 (premature trial termination after 5 eculizumab infusions because of complications of concomitant liver cirrhosis), no follow-up visits.
Imputed from week 24 (no lactate dehydrogenase value available in week 26).
Imputed from week −1 (no reliable hemoglobin value available in week 0).